EmersonALimMDMS

Oncology • Grand Rapids, MI

Genitourinary Oncology

Physician

Join to view full profile

Dr. Lim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lim's full profile

Already have an account?

Office
145 Michigan St NE
Suite 5200
Grand Rapids, MI 49503
Phone+1 616-486-6700

Fax+1 616-486-6705

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
New York University School of MedicineClass of 2006

Certifications & Licensure

MI State Medical License 2021 - 2027
NY State Medical License 2007 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers Start of enrollment: 2018 Dec 11
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

2 citations
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Gerald S Falchook, James Reeves, Sunil Gandhi, David R Spigel, Edward Arrowsmith
Cancer Immunology, Immunotherapy. 2024-03-02
6 citations
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Jessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, Emerson A Lim, Karie Runcie
Cancer Cell. 2023-11-13
7 citations
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen
Cancer Discovery. 2023-06-02

Lectures

A phase II study for prostate cancer monitoring using 18F-DCFPyL and blood-based biomarkers.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

MSU and Corewell Health Mark 17-Year Partnership by Adding $1M Investment in Exploratory ResearchNovember 25th, 2024
RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual MeetingApril 27th, 2020